Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 3,771 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 3,771 shares of the business’s stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $65.61, for a total transaction of $247,415.31. Following the transaction, the chief executive officer now directly owns 312,973 shares in the company, valued at approximately $20,534,158.53. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

William Lewis also recently made the following trade(s):

• On Tuesday, May 13th, William Lewis sold 17,442 shares of Insmed stock. The stock was sold at an average price of $66.97, for a total transaction of $1,168,090.74.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10.
• On Tuesday, April 15th, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $70.16, for a total transaction of $479,192.80.
• On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50.
• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50.

Insmed Stock Up 2.5%

INSM stock opened at $67.22 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The firm has a fifty day moving average price of $71.68 and a two-hundred day moving average price of $73.12. The firm has a market cap of $12.24 billion, a price-to-earnings ratio of -12.03 and a beta of 0.84.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm’s revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.06) EPS. Research analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on INSM. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Guggenheim restated a “buy” rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. UBS Group dropped their price target on shares of Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Wells Fargo & Company lifted their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.63.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently modified their holdings of INSM. Cullen Frost Bankers Inc. grew its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 221 shares during the last quarter. Elequin Capital LP bought a new position in shares of Insmed during the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC grew its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC grew its position in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 248 shares during the last quarter. Finally, Spire Wealth Management bought a new position in shares of Insmed during the fourth quarter worth about $47,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.